[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054743":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":10,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"healthy volunteers",null,"At least 18 years old and have no history of any medical illness that may confound study results or make participation in this protocol impossible",{"label":13,"type":10,"description":14,"interventionNames":10},"individuals seropositive for HTLV","Positive HTLV-1 ELISA followed by a positive Western Blot",{"label":16,"type":10,"description":17,"interventionNames":10},"individuals with indeterminate HTLV sero-status","Positive HTLV ELISA but a Western Blot that only partially fulfills criteria",[19],{"name":20,"affiliation":21,"role":22},"Steven Jacobson, Ph.D.","National Institute of Neurological Disorders and Stroke (NINDS)","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Daniel S Reich, M.D.","CONTACT","(301) 496-1801","reichds@ninds.nih.gov",{"name":20,"role":26,"phone":30,"phoneExt":10,"email":31},"(301) 496-0519","jacobsons@ninds.nih.gov",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-77.10026,38.98067,{"lat":45,"lon":44},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100054743","evaluation-of-patients-with-hamtsp-100054743",false,"NCT00001778","Evaluation of Patients With HAM\u002FTSP","Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM\u002FTSP)","* INCLUSION CRITERIA:\n\nParticipants that meet one of the following criteria:\n\n* Test positive for HTLV infection (positive HTLV-1 ELISA followed by a positive Western blot)\n* Positive HTLV ELISA but a Western Blot that only partially fulfills the above criteria (seroindeterminate)\n* Have a family member\u002Fsignificant other who is HTLV positive, and may have been exposed to the virus\n* Healthy volunteer AND\n* Willingness to participate in the protocol evaluations and procedures.\n\nEXCLUSION CRITERIA:\n\n* Unwillingness or inability to participate in the protocol evaluations and procedures.\n* The presence of any medical, social, or psychiatric conditions that in the opinion of the investigator may affect the safety of the patients or compliance with the protocol.\n* Patients\u002Fhealthy volunteers under the age of 18 are excluded.",true,"ALL","18 Years","120 Years",{"count":61,"type":62},750,"ESTIMATED","OBSERVATIONAL","Objective:\n\nHuman T-lymphotropic virus type-I-associated myelopathy \u002F tropical spastic paraparesis (HAM\u002FTSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM\u002FTSP by monitoring clinical progression of patients longitudinally. Additionally, we will attempt to define the virological and immunological changes of HAM\u002FTSP.\n\nStudy Population:\n\nPatients with HAM\u002FTSP who fulfill World Health Organization diagnostic criteria are eligible to participate in this protocol. Asymptomatic seropositive individuals and individuals with indeterminate HTLV-1 serology are also eligible to participate.\n\nDesign and Outcome Measures:\n\nA longitudinal assessment of clinical, virological and immunological progression in HAM\u002FTSP will be accomplished through periodic testing and evaluation. Asymptomatic seropositive individuals, those with seroindeterminate HTLV-I serology and normal volunteers may serve as controls. Longitudinal standardized neurological examinations will be performed. Longitudinal samples of serum, plasma, and lymphocytes may be obtained from participants. Lumbar punctures may be performed on all participants. These samples will be used virological and immunological assays. A focus is on the relationships between the characteristics of viral infection, the immune response, and the genetic makeup.\n\n...",[66,67],"HTLV-I Infection","Tropical Spastic Paraparesis",[69,70,71,72,73,74,75,76],"Immune Response","Sero-Indeterminant","Transmission","HTLV-1","HTLV-1 Associated Myelopathy","Natural History","HTLV-I","HAM\u002FTSP","2026-06-27",{"date":79,"type":80},"2026-06-30","ACTUAL",{"date":82,"type":80},"1998-04-06",{"name":21,"class":6},1]